Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742938 | 1.00 | MAOB (0.55) | MAOBMEN1KMT2ATAS1R3TAS1R1 | |
| SCHEMBL30837232 | 0.90 | ABL1 (0.55) | MAOBNPC1RAB9AABL1 | |
| SCHEMBL28079445 | 0.88 | MAOB (0.54) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL7927459 | 0.86 | MAOB (0.52) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17065159 | 0.86 | CES2 (0.51) | MAOBTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL2095019 | 0.86 | MAOB (0.52) | MAOBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL29236792 | 0.86 | MAOB (0.58) | MAOBMEN1KMT2ATAS1R3TAS1R1 | |
| SCHEMBL690501 | 0.85 | KAT6A (0.54) | MAOBTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL16959752 | 0.85 | TAS1R3 (0.48) | MAOBTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL2557596 | 0.85 | MAOB (0.51) | MAOBMEN1KMT2AKAT6ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612033-B2 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORP. (US) | 2009-11-03 | — | — | US | claimed |
| EP-1015039-B1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2008-08-27 | — | — | EP | claimed |
| EP-0935415-B1 | IN VITRO METHODS FOR DELIVERING NUCLEIC ACIDS INTO A CELL | IMARX PHARMACEUTICAL CORP (US) | 2006-11-22 | — | — | EP | claimed |
| US-7105151-B2 | Oxygen delivery agents and uses for the same | IMARX THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | claimed |
| US-20040176473-A1 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORP. | 2004-09-09 | — | — | US | claimed |
| US-6743779-B1 | NUCLEIC ACID SEQUENCE AND A FLUORINATED COMPOUND AND A LIPID CARRIER. | IMARX PHARMACEUTICAL CORP. | 2004-06-01 | — | — | US | claimed |
| US-6638767-B2 | Mixture containing organic halide | IMARX PHARMACEUTICAL CORPORATION | 2003-10-28 | — | — | US | claimed |
| US-20030120204-A1 | Oxygen delivery agents and uses for the same | CEREVAST THERAPEUTICS, INC. | 2003-06-26 | — | — | US | claimed |
| EP-1015039-A4 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-09-11 | — | — | EP | claimed |
| EP-0935415-A4 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP (US) | 2002-08-14 | — | — | EP | claimed |
| US-20010031740-A1 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORPORATION | 2001-10-18 | — | — | US | claimed |
| US-6143276-A | ADMINISTERING TO THE PATIENT A COMPOSITION COMPRISING A BIOACTIVE AGENT AND A GASEOUS PRECURSOR CAPABLE OF UNDERGOING PHASE TRANSITION TO A GAS AT A REGION OF ELEVATED TEMPERATURE IN THE PATIENT | IMARX PHARMACEUTICAL CORP. (US) | 2000-11-07 | — | — | US | claimed |
| EP-1046394-A2 | Novel compositions useful for delivering compounds into a cell | ImaRx Pharmaceutical Corp. (US) | 2000-10-25 | — | — | EP | claimed |
| EP-1015039-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | claimed |
| EP-0935415-A1 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1999025385-A1 | A METHOD OF INCREASING NUCLEIC ACID SYNTHESIS WITH ULTRASOUND | IMARX PHARMACEUTICAL CORP. (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1998057670-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | claimed |
| WO-1997040679-A1 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP. (US) | 1997-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176473-A1 | Methods for delivering compounds into a cell | ABCB4, NPC1L1, IAPP | MAOB 3210/4885MEN1 1692/4885KMT2A 4067/4885 |
| US-20010031740-A1 | Methods for delivering compounds into a cell | ABCB4, NPC1L1, IAPP | MAOB 3210/4885MEN1 1692/4885KMT2A 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.